In a recent trial, Sindher’s team found that the injectable medication omalizumab reduces the risk of allergic reactions. Omalizumab is now FDA-approved for children one year and older, either alone ...

Phase II data suggest remibrutinib could compete with approved injectable ...

Phase II data suggest fewer GI adverse effects when given a sequence of biologics ...

AIM-listed biotech reports biomarker results suggesting its VLP Peanut treatment could work in as few as three injections ...

He has had no issue taking the injections but now he knows what’s coming and bounces around too much for me to give him an injection.

The Worthing, England-based biotechnology company said VLP Peanut, its new anti-allergy product under testing, shows a "significant" reduction in basophil sensitivity, and that both downward allergen ...

Neffy nasal spray shows comparable efficacy to IM epinephrine for type I allergic reactions, with 92.3% symptom resolution after 1 dose.

Great. Thank you for coming, everybody. I'm James Gordon, Barclays European pharma and biotech analyst. And today, I've got the pleasure of hosting a fireside with GSK. So we're going to hear from GSK ...

A comprehensive thyroid approach involves the use of more tests, and an evaluation of symptoms, nutrients, labs, and ...

Researchers at UCLA have found a way to supercharge immune cells with a fuel source that tumors can't steal, dramatically ...

Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.

We chose the best dog foods with guidance from veterinarians. Our top picks include dry, wet, and fresh food for adults, ...